DDInter856 DDInter283
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
Cangrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Cangrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Cangrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Cangrelor {u} may lead to a major life threatening interaction when taken with {v} Alteplase
Cangrelor {u} may lead to a major life threatening interaction when taken with {v} Tinzaparin
Cangrelor may cause a minor interaction that can limit clinical effects when taken with Turmeric
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Cangrelor may lead to a major life threatening interaction when taken with Alteplase
Cangrelor may lead to a major life threatening interaction when taken with Tinzaparin